Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. - Wikidata - wikimedia - TriplyDB

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.

http://www.wikidata.org/entity/Q33387339

about

Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas.A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis Bortezomib treatment causes long-term testicular dysfunction in young male mice.Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside Management of indolent lymphoma: where are we now and where are we going.Bortezomib for the treatment of non-Hodgkin's lymphoma Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.Therapeutic options for HIV-associated lymphomas.Follicular lymphoma: emerging therapeutic strategies.Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma.Genetic and molecular targets in lymphoma: implications for prognosis and treatment.Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?Targeting mTOR for the treatment of B cell malignancies.The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.Novel agents in indolent lymphomas.A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study.Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities.Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study.The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.

P2860

Q24298561-5296AFD6-25CB-437D-9CC9-DC5776D5F284 Q33391725-FB0B3342-2EF3-44AC-ADA9-EE3D9C6E9DB6 Q33394689-1A2721A1-CA91-4A0C-B10F-FB5B354F653A Q33402885-227FD2C4-1D49-41E4-A5B0-D4A9889B102B Q33403958-C1A07CB4-17AA-493A-BD10-72F76C42A7D2 Q33404090-CD031A9B-C4D8-4416-8E62-5983F45BEC79 Q33413834-1CE0AC5D-0FD4-4DB9-B7B0-BB949762015C Q33414243-E74E943E-7FD5-4EF2-BE35-4652FFE94C69 Q33414603-65576A09-EB2C-42E8-B36A-9645856BE2F6 Q33416533-5C51F444-8387-4A78-9522-65016243AE24 Q33417803-B9772F21-BE65-4F06-A477-861F87700571 Q33418257-7093D7DE-AEC2-490F-9574-AB946D749CA9 Q33419346-92B1DE31-63F6-4C58-8530-7F48FEE5E6DB Q33424956-2A017682-4511-436A-89B4-F161BB17C57D Q33439441-95092705-61CF-400D-8BD1-7B8DE7FFEEA4 Q33690142-C85398D5-6F62-419A-9CDD-F71C1715BD5F Q33713106-1B6E63F5-8CFD-4076-8368-FD5892E67139 Q33819331-61FDB21F-4F2B-41F4-9A13-06D65610A1E6 Q34542087-AEB5EAB8-FB5B-4DF3-A7F7-81DF2F0C918B Q34788381-386B81DE-3EF9-459E-97B2-627E00642A3F Q35050501-358BB186-9346-435B-8953-9B15B675DEBD Q35561291-176786A9-A351-4D83-9E75-82FED27FB6DA Q35905929-CD1CD66F-5A9F-4174-A974-AD55EAAB4EFF Q35989980-3C119DF0-A796-4C80-A877-81F885D68273 Q36784860-3CDE41DA-24B6-4F97-B030-042E2CF6556C Q36868056-39D31D97-AB70-4E5D-9D64-1CDBB22F77CD Q37327280-41511187-4D25-4DC6-B816-1D2B0AB0159C Q37524930-42D5EBF5-5648-444A-A8E9-F70ED6CC26CC Q37781368-BC0C3467-2645-4B65-A06D-CD69B1AA3113 Q37810129-EF864552-C6D6-49FE-BC04-0D2F2487F486 Q38034939-4364BEE5-95AE-4737-8246-ED99DD5B4970 Q38294626-3099C761-D139-4A40-90FE-58085EE6B8C8 Q38568358-00E14504-36F4-4B16-9D17-37D0614DB40F Q38709825-7D704842-110E-4903-8BB8-51DF927FA065 Q39029195-670432EA-3D77-4641-838C-95E56347AAF8 Q39431412-92A97B47-AEBE-4611-AB34-E3CDE4CCDA85 Q41665957-59157A10-CFE1-4B29-9385-BDE52EAA067C Q43138254-55C1184C-69CC-4104-8AAD-1C4D8BEC47E5 Q46130238-B80D9984-2F4F-4E30-A859-A2D7A37254CB Q49226138-09CBFB4B-7325-462C-AC4C-4FA274F60369

P2860

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.

http://www.wikidata.org/entity/Q33387339

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Results of a phase 2 study of ...... refractory indolent lymphoma.

@ast

Results of a phase 2 study of ...... refractory indolent lymphoma.

@en

type

label

Results of a phase 2 study of ...... refractory indolent lymphoma.

@ast

Results of a phase 2 study of ...... refractory indolent lymphoma.

@en

prefLabel

Results of a phase 2 study of ...... refractory indolent lymphoma.

@ast

Results of a phase 2 study of ...... refractory indolent lymphoma.

@en

P1433

Q33387339-5BA7F816-014A-4056-B9F6-FFDAFCC41D30

P1476

Q33387339-CB202346-748A-4F71-A13C-C3836634133C

P2093

Q33387339-0626EE12-E648-4703-A638-85CEEA2DC571

Q33387339-16DDA0E0-6E55-43D7-98FD-0E74693B4E1F

Q33387339-21956B91-4A21-48D0-8F1F-2180DC8F0521

Q33387339-245476A2-51E5-4871-86BF-880E194B8605

Q33387339-2EF13058-68B9-43DB-8DFF-5E162A80D409

Q33387339-2FBBA989-D699-40CC-B513-414630A91780

Q33387339-3AB274B6-065A-4B4D-B57E-8025C0AC629C

Q33387339-42C888DD-1C77-4276-A045-2B11488A3426

Q33387339-563E6450-435B-4982-BC93-0C1139C6CD07

Q33387339-5CC2B4BB-89F5-442A-922C-CFC1393D39CD

P304

Q33387339-A018DB09-C74D-47E0-AB64-4513BDCA1857

P31

Q33387339-FE9F2B8D-548C-46EA-9D9A-8FD883991992

P356

Q33387339-86EB2B83-3EB7-4531-BF39-E1BEC7496F02

P407

Q33387339-D34E4CFB-0BAC-4881-A8F5-03EC5CC733A4

P433

Q33387339-FE9F5273-8B12-4585-9979-720F7B304C73

P478

Q33387339-ACA3B8B5-2DE8-4D05-99DF-909D2900F731

P577

Q33387339-E6EDA0C6-D881-4255-9F18-D31EDA147FBD

P5875

Q33387339-695B1C46-5D5A-434F-A6B2-AAB06B67A4FD

P698

Q33387339-69791279-D8DD-467B-9513-63D9F10E9486

P356

BLOOD-2009-08-233155

P1433

P1476

Results of a phase 2 study of ...... refractory indolent lymphoma.

@en

P2093

David Barrera

http://www.w3.org/2001/XMLSchema#string

Ernest W Cochran

http://www.w3.org/2001/XMLSchema#string

Julie Boston

http://www.w3.org/2001/XMLSchema#string

Kathryn Kolibaba

http://www.w3.org/2001/XMLSchema#string

Kristi A Boehm

http://www.w3.org/2001/XMLSchema#string

Lina Asmar

http://www.w3.org/2001/XMLSchema#string

Nicholas Di Bella

http://www.w3.org/2001/XMLSchema#string

Peter J Schlegel

http://www.w3.org/2001/XMLSchema#string

Philip Y Dien

http://www.w3.org/2001/XMLSchema#string

Raymond Taetle

http://www.w3.org/2001/XMLSchema#string

P304

475-480

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-08-233155

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40452658

http://www.w3.org/2001/XMLSchema#string

P698

19965689

http://www.w3.org/2001/XMLSchema#string